Stocks / Pharmaceuticals
NVOPharmaceuticals
Novo-Nordisk A/S
$43.431d +3.7%5d -1.4%settled close · 2026-09-17
The tape, with the calls on it
Who said what, and what NVO did next
Every dot is a day someone on the record made a call. Hover one to see who. We are not scoring them — the point is that you can see it and judge for yourself.
bullish
bearish
both sides
Who’s talkingIdea Scout · free
Who’s talking about NVO
5 long1 shortlatest 2026-01-13
| Date | Voice | Stance | Venue | Thesis |
|---|---|---|---|---|
| 2026-01-13 | Karen Finerman (Metropolitan)CEO, Metropolitan Capital Advisors | Bullish | CNBC Fast Money Final Trade | Novo Nordisk holds a first-mover lead in the oral GLP-1 space, giving it a durable competitive advantage in… |
| 2026-01-05 | Carter WorthMarket technician, Worth Charting | Bullish | CNBC Fast Money Final Trade | Novo Nordisk has completed a bearish-to-bullish technical reversal, signaling a buy entry |
| 2025-12-23 | Tim Seymour (Seymour Asset Mgmt)CIO, Seymour Asset Management | Bullish | CNBC Fast Money Final Trade | Contrarian hold on Novo Nordisk despite near-term headwinds, sticking with the name as a final trade… |
| 2025-10-08 | Karen Fast Money PanelistCEO, Metropolitan Capital Advisors | Bullish | CNBC Fast Money Final Trade | Novo Nordisk offers exposure to the GLP-1/obesity drug space as an alternative to Eli Lilly, which the… |
| 2024-09-26 | Terry SmithFounder & CIO, Fundsmith | Bullish | Financial Planner Life Podcast | Novo Nordisk is the one pharmaceutical holding within Fundsmith's medical-technology allocation, positioned… |
| 2024-02-18 | Freddie LaitManaging Partner & CIO, Latitude Investment Management | Bearish | Business Breakdowns | Exited a multi-year long position in Novo Nordisk purely on valuation grounds, while arguing GLP-1 drugs'… |
Idea Scout tracks who’s
talking across television, podcasts, and interviews — every stance
dated to the appearance it came from.
Sign up free →
The options tapeThe Brief · paid
Notable options days
Sessions in the last 120 where NVO’s settled options volume ran ≥ 2× its trailing 20-session baseline, or delta-dollar flow ran ≥ 2.5× — 2 of 120 sessions qualified.
The qualifying dates are the free record. Close, flow, call/LEAPS mix and the 20-session outcome — for every session below — are Brief subscriber content.
| Date | Close | RVOL | Δ$ flow ($M) | Call % | LEAPS % | +20 sess. |
|---|---|---|---|---|---|---|
| 2026-08-04 | ||||||
| 2026-07-31 |
+20 sess. = raw price change over the following 20
sessions — not market-adjusted; the tape tells you where to look,
not what happens next.
Today’s tape on
NVO is in this morning’s Brief.
Get The Brief — $20/mo →